KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.90

Subcutaneous versus intravenous nivolumab for renal cell carcinoma.

L Albiges, M T Bourlon, M Chacón, H J Cutuli, Y A L Chuken, B Żurawski, J M Mota, I Magri, M Burotto, M Luz, J de Menezes, E P Y Ruiz, S Fu, M Richardet, B P Valderrama, M Maruzzo, S Bracarda, M Breckenridge, H E Vezina, D Rathod, Z Yu, Y Zhao, M Dixon, D Perumal, S George

Ann Oncol 36(1) 99-107

PMID39288844
PMCID-
DOI10.1016/j.annonc.2024.09.002
发表日期2024-09-17
入排依据:The study is an oncology, human, randomized, Phase III trial with a drug-containing intervention (nivolumab) and reports original results. However, the primary endpoint is pharmacokinetic non-inferiority, and the key secondary endpoint is objective response rate (ORR), which is not a time-to-event efficacy endpoint. No time-to-event endpoints (OS, PFS, DFS, EFS, RFS, TTP) or associated Kaplan-Meier/HR analyses are reported or indicated.
摘要

摘要

BACKGROUND: The evolving oncology treatment paradigm has created an unmet need for administration options that improve patient experiences and health care efficiencies. PATIENTS AND METHODS: CheckMate 67T (NCT04810078) was a phase III, open-label, multicenter, noninferiority trial in which patients with advanced/metastatic clear cell renal cell carcinoma were randomized to subcutaneous nivolumab (1200 mg every 4 weeks; coformulated with recombinant human hyaluronidase PH20 20 000 units) or intravenous nivolumab (3 mg/kg every 2 weeks). The primary objective was to assess the noninferiority of subcutaneous versus intravenous nivolumab by coprimary endpoints determined from a population pharmacokinetics analysis [time-averaged serum concentration over the first 28 days (Cavgd28), and minimum steady-state serum concentration (Cminss); noninferiority threshold: lower boundary of 90% confidence interval (CI) of the geometric mean ratios (GMR) ≥0.8]. Objective response rate (ORR) was a key secondary endpoint powered for noninferiority [noninferiority threshold: lower boundary of 95% CI of relative risk of ORR (subcutaneous versus intravenous nivolumab) ≥0.60]. RESULTS: Overall, 495 patients were randomized. Relative exposure in the subcutaneous versus intravenous arm reported by the GMR of Cavgd28 and Cminss was 2.098 (90% CI 2.001-2.200) and 1.774 (90% CI 1.633-1.927), respectively. After 8 months of minimum follow-up, ORR was 24.2% with subcutaneous nivolumab (95% CI 19.0%-30.0%) versus 18.2% with intravenous nivolumab [95% CI 13.6%-23.6%; relative risk: 1.33 (95% CI 0.94-1.87)]. Coprimary endpoints and ORR met noninferiority thresholds. Additional efficacy and safety measures were similar. CONCLUSIONS: Subcutaneous nivolumab was noninferior to intravenous nivolumab based on pharmacokinetics and ORR. No new safety signals were observed.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。